[go: up one dir, main page]

MX360697B - Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias. - Google Patents

Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias.

Info

Publication number
MX360697B
MX360697B MX2013012282A MX2013012282A MX360697B MX 360697 B MX360697 B MX 360697B MX 2013012282 A MX2013012282 A MX 2013012282A MX 2013012282 A MX2013012282 A MX 2013012282A MX 360697 B MX360697 B MX 360697B
Authority
MX
Mexico
Prior art keywords
diseases
treatment
conditions
degenerative
inflammatory diseases
Prior art date
Application number
MX2013012282A
Other languages
English (en)
Other versions
MX2013012282A (es
Inventor
Jeanne Marie Menet Christel
James Hodges Alastair
David Vater Huw
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2013012282A publication Critical patent/MX2013012282A/es
Publication of MX360697B publication Critical patent/MX360697B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describe un compuesto de pirazolopiridina de acuerdo con la fórmula I, capaz de inhibir JAK así como sales farmacéuticamente aceptables, un solvato del mismo, solvatos de las sales farmacéuticamente aceptables y metabolito biológicamente activo del mismo. El compuesto se puede preparar como una composición farmacéutica y se puede utilizar para el tratamiento o profilaxis de una variedad de condiciones en mamíferos que incluye humanos y particularmente condiciones las cuales se pueden asociar con actividad aberrante de JAK, que incluyen, a modo de ejemplo no limitante, alergia, condiciones inflamatorias, enfermedades autoinmunes, enfermedades proliferativas, rechazo de transplantes, enfermedades que involucran deterioro de recambio de cartílago, malformaciones congénitas de cartílago y/o enfermedades asociadas con hipersecreción de IL6.
MX2013012282A 2011-04-28 2012-04-26 Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias. MX360697B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161479956P 2011-04-28 2011-04-28
PCT/EP2012/057652 WO2012146657A1 (en) 2011-04-28 2012-04-26 Novel compound useful for the treatment of degenerative and inflammatory diseases

Publications (2)

Publication Number Publication Date
MX2013012282A MX2013012282A (es) 2013-11-21
MX360697B true MX360697B (es) 2018-11-14

Family

ID=46017860

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013012282A MX360697B (es) 2011-04-28 2012-04-26 Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias.
MX2013012281A MX355653B (es) 2011-04-28 2012-04-26 Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013012281A MX355653B (es) 2011-04-28 2012-04-26 Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.

Country Status (18)

Country Link
US (5) US8975406B2 (es)
EP (2) EP2702058B1 (es)
JP (2) JP5947371B2 (es)
KR (1) KR101934707B1 (es)
CN (2) CN103492386B (es)
AR (1) AR086042A1 (es)
AU (2) AU2012247484B2 (es)
BR (1) BR112013027338A2 (es)
CA (2) CA2833942A1 (es)
EA (1) EA024743B1 (es)
HK (2) HK1195311A1 (es)
IL (1) IL228786A (es)
MX (2) MX360697B (es)
SG (1) SG194508A1 (es)
TW (1) TWI536990B (es)
UY (1) UY34037A (es)
WO (2) WO2012146659A1 (es)
ZA (1) ZA201307793B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
US20160074318A1 (en) * 2013-04-29 2016-03-17 Sanofi Sa Inhalable Pharmaceutical Compositions and the Inhaler Devices Containing Them
GB201321733D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR101690760B1 (ko) * 2014-11-05 2016-12-30 조길래 피부자극완화, 탈모방지 및 발모촉진 효과를 나타내는 카페오일펜타펩타이드 및 이를 함유하는 탈모방지 및 발모촉진용 화장료 조성물
TW201705961A (zh) * 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
US10919875B2 (en) 2015-06-18 2021-02-16 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivatives
KR20180026459A (ko) * 2015-06-18 2018-03-12 세파론, 인코포레이티드 1,4-치환된 피페리딘 유도체
LT3322706T (lt) 2015-07-16 2021-03-10 Array Biopharma, Inc. Pakeistieji pirazolo[1,5-a]piridino junginiai, kaip ret kinazės inhibitoriai
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
DE102015215820A1 (de) * 2015-08-19 2017-02-23 Siemens Healthcare Gmbh Steuern eines medizintechnischen Geräts
WO2018019222A1 (zh) * 2016-07-26 2018-02-01 张文燕 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) * 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
WO2018163971A1 (ja) * 2017-03-09 2018-09-13 富士フイルム株式会社 音響レンズ用樹脂材料、音響レンズ、音響波プローブ、音響波測定装置、超音波診断装置、光音響波測定装置および超音波内視鏡
EA037208B1 (ru) * 2017-09-29 2021-02-19 Эррей Биофарма Инк. ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA035568B1 (ru) * 2017-09-29 2020-07-08 Эррей Биофарма Инк. ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
TWI783057B (zh) 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
TW202410896A (zh) * 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
JP7493251B2 (ja) * 2018-09-30 2024-05-31 北京志健金瑞生物医▲薬▼科技有限公司 ピラゾール置換縮合環誘導体並びにその製造方法及び応用
CN111285873B (zh) 2018-12-07 2024-10-15 广东东阳光药业股份有限公司 Ret抑制剂、其药物组合物及其用途
US20220119382A1 (en) * 2018-12-07 2022-04-21 Sunshine Lake Pharma Co., Ltd. Ret inhibitors, pharmaceutical compositions and uses thereof
EP4141003A4 (en) * 2020-04-22 2024-05-15 Shenzhen Zhongge Biological Technology Co., Ltd. PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND ASSOCIATED COMPOSITION AND USE
CN113713083A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种用于治疗脱发的药物组合
JP2023540274A (ja) 2020-09-01 2023-09-22 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 硫黄含有置換基を有する殺有害生物的に活性な複素環式誘導体
WO2022064459A1 (en) 2020-09-28 2022-03-31 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
US20240158392A1 (en) * 2021-02-01 2024-05-16 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
US20240174662A1 (en) * 2021-02-01 2024-05-30 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
WO2023017094A1 (en) 2021-08-10 2023-02-16 Syngenta Crop Protection Ag 2,2-difluoro-5h-[1,3]dioxolo[4,5-f]isoindol-7-one derivatives as pesticides
CN114409675B (zh) * 2022-01-07 2023-08-04 重庆医科大学 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
WO2023187191A1 (en) 2022-04-01 2023-10-05 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2024156664A1 (en) 2023-01-23 2024-08-02 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2427046T3 (es) 2004-06-21 2013-10-28 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
US8883820B2 (en) * 2006-08-30 2014-11-11 Cellzome Ltd. Triazole derivatives as kinase inhibitors
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
KR20110033223A (ko) * 2008-06-20 2011-03-30 제넨테크, 인크. 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica

Also Published As

Publication number Publication date
WO2012146659A1 (en) 2012-11-01
EA201391584A1 (ru) 2014-04-30
US20140051677A1 (en) 2014-02-20
CA2833942A1 (en) 2012-11-01
NZ617528A (en) 2015-09-25
AU2012247484A1 (en) 2013-03-28
WO2012146657A1 (en) 2012-11-01
CN103492386B (zh) 2016-03-09
MX355653B (es) 2018-04-26
US9987272B2 (en) 2018-06-05
US8975406B2 (en) 2015-03-10
EA024743B1 (ru) 2016-10-31
MX2013012282A (es) 2013-11-21
KR20140025430A (ko) 2014-03-04
BR112013027338A2 (pt) 2017-08-08
AR086042A1 (es) 2013-11-13
SG194508A1 (en) 2013-12-30
IL228786A0 (en) 2013-12-31
EP2702058A1 (en) 2014-03-05
HK1195312A1 (zh) 2014-11-07
US20150031706A1 (en) 2015-01-29
EP2702059A1 (en) 2014-03-05
US9241931B2 (en) 2016-01-26
US20120277247A1 (en) 2012-11-01
US20160213666A1 (en) 2016-07-28
CA2833963C (en) 2019-09-17
CN103492385A (zh) 2014-01-01
EP2702059B1 (en) 2015-08-19
MX2013012281A (es) 2013-11-21
JP2014512404A (ja) 2014-05-22
CN103492386A (zh) 2014-01-01
KR101934707B1 (ko) 2019-01-03
AU2012247482B2 (en) 2015-03-05
JP2014512405A (ja) 2014-05-22
AU2012247484B2 (en) 2015-02-19
US20180078547A1 (en) 2018-03-22
ZA201307793B (en) 2015-04-29
AU2012247482A1 (en) 2013-03-28
JP5947372B2 (ja) 2016-07-06
HK1195311A1 (zh) 2014-11-07
EP2702058B1 (en) 2015-08-19
CN103492385B (zh) 2016-05-11
CA2833963A1 (en) 2012-11-01
IL228786A (en) 2017-04-30
JP5947371B2 (ja) 2016-07-06
UY34037A (es) 2012-11-30
TWI536990B (zh) 2016-06-11
US8802682B2 (en) 2014-08-12
TW201247202A (en) 2012-12-01

Similar Documents

Publication Publication Date Title
MX2013012282A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
PH12014502615B1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
MY161095A (en) Indole compound and pharmaceutical use thereof
GB2483424A (en) 5-Phenyl-[1,2,4] triazolo[1,5-A] pyridin-2-yl carboxamides as JAK inhibitors
MX2011013451A (es) Nuevo compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias.
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
PH12020550230A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EA201390198A1 (ru) Гетероциклическое соединение
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
PH12013501574A1 (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
PH12013501591A1 (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
PH12015500376A1 (en) Novel bicyclic pyridinones
MX2014002936A (es) Nuevos derivados de acido betulinico con actividad antiviral.
TN2014000001A1 (en) A new therapeutical composition containing apomorphine as active ingredient
PH12016501677B1 (en) Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IN2013DN02555A (es)
MX2013005825A (es) Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2013005821A (es) Benzoxazepinas como inhibidores de fosfatidilinositol/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
MY164134A (en) Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
UA105796C2 (uk) Сполука, застосовна для лікування дегенеративних і запальних захворювань

Legal Events

Date Code Title Description
FG Grant or registration